ethyl 4-(aminomethyl)cyclohexane-1-carboxylate | 35879-53-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 4-(aminomethyl)cyclohexane-1-carboxylate
• 英文别名: trans-4-aminomethylcyclohexanecarboxylic acid ethyl ester；ethyl (1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylate；trans-ethyl 4-(aminomethyl)cyclohexanecarboxylate；trans-4-aminomethyl-cyclohexanecarboxylic acid ethyl ester；ethyl trans-4-aminomethylcyclohexane-1-carboxylate；ethyl trans 4-(aminomethyl)cyclohexanecarboxylate；ethyl trans-4-(aminomethyl)cyclohexanecarboxylate
• CAS: 35879-53-9
• 化学式: C₁₀H₁₉NO₂
• 分子量: 185.266
• InChiKey: YKPFISPUYINSAF-KYZUINATSA-N

物化性质

• 沸点：
  259.3±13.0 °C(Predicted)
• 密度：
  0.999±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.31
• 重原子数：
  13.0
• 可旋转键数：
  3.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  52.32
• 氢给体数：
  1.0
• 氢受体数：
  3.0

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  ethyl 4-(aminomethyl)cyclohexane-1-carboxylate 在 二异丁基氢化铝 、 三乙胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 生成 trans 4-(tert-butyloxycarbonylaminoethyl)cyclohexaneacetaldehyde
  参考文献：
  名称：

  A Structure–Activity Analysis of Biased Agonism at the Dopamine D2 Receptor

  摘要：

  Biased agonism offers an opportunity for the medicinal chemist to discover pathway-selective ligands for GPCRs. A number of studies have suggested that biased agonism at the dopamine D2 receptor (D2R) may be advantageous for the treatment of neuropsychiatric disorders, including schizophrenia. As such, it is of great importance to gain insight into the SAR of biased agonism at this receptor. We have generated SAR based on a novel D2R partial agonist, tert-butyl (trans-4-(2-(3,4dihydroisoquinolin-2(1H)-yOethyl)cyclohexyl)carbamate (4). This ligand shares structural similarity to cariprazine (2), a drug awaiting FDA approval for the treatment of schizophrenia, yet displays a distinct bias toward two different signaling end points. We synthesized a number of derivatives of 4 with subtle structural modifications, including incorporation of cariprazine fragments. By combining pharmacological profiling with analytical methodology to identify and to quantify bias, we have demonstrated that efficacy and biased agonism can be finely tuned by minor structural modifications to the head group containing the tertiary amine, a tail group that extends away from this moiety, and the orientation and length of a spacer region between these two moieties.

  DOI：

  10.1021/jm401318w
• 作为产物：
  描述：

  tranexamic acid 在 硫酸 作用下， 以 乙醇 为溶剂， 反应 17.0h， 以55%的产率得到ethyl 4-(aminomethyl)cyclohexane-1-carboxylate
  参考文献：
  名称：

  Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them

  摘要：

  公式（I）所选的化合物如下： 其中： X代表氧或硫， Y代表氧，-NH-或-N（C1-C6）烷基-， Ra代表氢，卤素，（C1-C3）烷基，羟基或（C1-C3）甲氧基， Rb代表氢，卤素或（C1-C3）烷基， A代表苯基，吡啶基，（C5-C6）环烷基或（C5-C6）环烯基， R1和R2分别代表从氢，卤素，氰基，硝基，卤代烷基，卤代甲氧基，烷基，烯基，炔基，-OR4，-NR4R5，-S（O）nR4，-C（O）R4，-CO2R4，-O—C（O）R4，-C（O）NR4R5，-NR5—C（O）R4，-NR5—SO2R4，-T-CN，-T-OR4，-T-OCF3，-T-NR4R5，-T-S（O）nR4，-T-C（O）R4，-T-CO2R4，-T-O—C（O）R4，-T-C（O）NR4R5，-T-NR4—C（O）R5，-T-NR4—SO2R5，-R6和-T-R6中选择的基团，其中n，T，R4，R5和R6如描述中所定义， R3代表-R7或-U-R11基团，其中R7代表氢，烷基，芳基，环烷基或杂环烷基，U代表线性或支链烷基链，R11如描述中所定义， 它们的光学异构体或它们与药学上可接受的酸或碱形成的加合盐，以及它们作为金属蛋白酶抑制剂，更具体地是金属蛋白酶-12的抑制剂的用途。

  公开号：

  US20040072871A1

文献信息

• [EN] TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER<br/>[FR] PRODUITS RADIOPHARMACEUTIQUES CIBLÉS POUR LE DIAGNOSTIC ET LE TRAITEMENT DU CANCER DE LA PROSTATE
  申请人：BAYER AS

  公开号：WO2021013978A1

  公开（公告）日：2021-01-28

  A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.

  通用式(I)的化合物：其中：n为1、2或3；R1、R2、R3和R4独立地代表OH或Q；Q代表从群组中选择的组织靶向基团，或其立体异构体、水合物、溶剂合物、盐或其混合物，制备所述化合物的方法，用于制备所述化合物的中间化合物，包含所述化合物的药物组合物和组合物，以及用于制造用于治疗或预防疾病的药物组合物的所述化合物的用途，特别是软组织疾病的治疗或预防，作为唯一药剂或与其他活性成分结合使用。
• Production of Copolyester Monomers from Plant‐Based Acrylate and Acetaldehyde
  作者：Lin Yuan、Yancheng Hu、Zhitong Zhao、Guangyi Li、Aiqin Wang、Yu Cong、Feng Wang、Tao Zhang、Ning Li

  DOI：10.1002/anie.202113471

  日期：2022.1.21

  alternative route is developed to prepare PCTA monomer with plant-based acrylate and acetaldehyde as the feedstocks. The features include catalytic MBH reaction, one-step dehydration/Diels–Alder reaction over H2SO4/SiO2 catalyst, and Pd/C-catalyzed dehydrogenation. In addition, commonly used plasticizer di(2-ethylhexyl) benzenedicarboxylate and monomer UNOXOL™ diol can also be manufactured.

  开发了一种替代路线，以植物基丙烯酸酯和乙醛为原料制备 PCTA 单体。其特征包括催化MBH反应、H 2 SO 4 /SiO 2催化剂上的一步脱水/Diels-Alder反应和Pd/C催化脱氢。此外，还可生产常用的增塑剂二（2-乙基己基）苯二甲酸酯和单体UNOXOL™二醇。
• DO3A-아미노메틸사이클로헥산 콘쥬게이트를 포함하는 가돌리늄 착물
  申请人：Kyungpook National University Industry-Academic Cooperation Foundation 경북대학교 산학협력단(220040016844) BRN ▼504-82-09678

  公开号：KR20150083721A

  公开（公告）日：2015-07-20

  본 발명은 가돌리늄 착물을 함유하는 MRI 조영제에 관한 것으로, 더욱 구체적으로 화학식 1의 구조를 갖는 DO3A-아미노메틸사이클로헥산 유도체 화합물과 그들의 가돌리늄 착물에 관한 것이다.본 발명에 따르면 DO3A-아미노메틸사이클로헥산 유도체 화합물을 제조할 수 있으며, 상기 화합물을 이용하여 가돌리늄 착물을 제조할 수 있다. 본 발명에 따라 제조된 가돌리늄 착물들은 열역학적 및 속도론적 안정성을 보여주고, 현재 상용중인 임상적 조영제와 필적할만한 이완율을 나타냈다. 따라서 본 발명에 따른 가돌리늄 착물은 자기공명영상(MRI)의 조영제로서 널리 사용될 수 있다.

  本发明涉及含有钆络合物的MRI造影剂，更具体地涉及具有化学式1结构的DO3A-氨甲基环己烷衍生物化合物及其钆络合物。根据本发明，可以制备DO3A-氨甲基环己烷衍生物化合物，并利用这些化合物制备钆络合物。根据本发明制备的钆络合物表现出热力学和动力学稳定性，并显示出与目前市售的临床造影剂相当的弛豫率。因此，根据本发明的钆络合物可以广泛用作磁共振成像（MRI）造影剂。
• Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines
  申请人：NEUROGEN CORPORATION

  公开号：US20030036652A1

  公开（公告）日：2003-02-20

  Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.

  提供了能够调节NPY5受体活性的替代螺环[异苯并呋喃-1,4′-哌啶]-3-酮和3H-螺环异苯并呋喃-1,4′-哌啶。这些化合物可用于在体内或体外调节NPY5受体的配体结合，并且在治疗各种疾病（例如，肥胖或暴食症等进食障碍、精神障碍、糖尿病和高血压等心血管疾病）方面对人类、驯养的伴侣动物和家畜动物特别有用。提供了用于治疗这些疾病的药物组合物和方法，以及用于检测NPY5受体的这些化合物的方法。
• Pharmaceutical composition for treating nephritis and method for
  申请人：Kureha Kagaku Kogyo Kabushiki Kaisha

  公开号：US04578404A1

  公开（公告）日：1986-03-25

  Disclosed herein are a pharmaceutical composition for treating nephritis, comprising at least one compound selected from the group consisting of the derivatives of N-(dihdyroxybenzylidene)amino acid, represented by the formula (I): ##STR1## wherein R represents an alkylene group having one to five carbon atoms, a phenylene group or ##STR2## the pharmaceutically acceptable salts and esters thereof, and a pharmaceutically acceptable carrier therefor, and the method for treating nephritis.

  本文公开了一种用于治疗肾炎的制药组合物，包括至少选自衍生物组成的化合物，该衍生物由式(I)表示的N-(二羟基苯甲酰亚胺)氨基酸衍生物组成：##STR1## 其中R代表具有1至5个碳原子的烷基基团，苯基基团或##STR2## 其药学上可接受的盐和酯，以及药学上可接受的载体，并提供了治疗肾炎的方法。